Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DateTimeSourceHeadlineSymbolCompany
29/05/202400:31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202422:47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
17/05/202406:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202422:47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202422:47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202422:00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202423:45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202423:47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
08/02/202400:47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
25/01/202400:47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
23/01/202409:02Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
20/01/202408:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/01/202408:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
20/01/202408:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
09/01/202409:02Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
09/01/202400:47GlobeNewswire Inc.Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitNASDAQ:CYTOAltamira Therapeutics Ltd
30/12/202300:47GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
12/12/202300:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
12/12/202300:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
12/12/202300:00GlobeNewswire Inc.Altamira Therapeutics Provides Investor and Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
09/12/202301:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
06/12/202304:54GlobeNewswire Inc.Altamira Therapeutics to Host Investor & Business Update Call on December 11thNASDAQ:CYTOAltamira Therapeutics Ltd
30/11/202302:20GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
23/11/202308:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
22/11/202300:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
18/11/202301:04GlobeNewswire Inc.Altamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNASDAQ:CYTOAltamira Therapeutics Ltd
11/11/202300:47GlobeNewswire Inc.Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNASDAQ:CYTOAltamira Therapeutics Ltd
01/11/202307:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
05/10/202300:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO